
Glucagon-Like Peptide-1 (GLP-1) receptor agonists are revolutionizing healthcare and the insurance landscape. Initially developed for type 2 diabetes management, these therapies are increasingly being adopted for obesity management, leading to significant implications for medical practices, healthcare costs, and insurance structures. The Rise of GLP-1 Therapies Increasing Prescription Spending The uptake of GLP-1 medications has led to a noticeable rise in